Abstract
Nitrofurantoin lung toxicity was diagnosed among ten patients receiving 50 mg/day to prevent recurrent urinary tract infection. In six patients a symptomatic period of 3-36 months preceded the diagnosis. All but one patient, with irreversible lung injury at presentation recovered completely, five after drug discontinuation and four after steroids therapy. Large amount of data regarding unexpected, sometimes severe pulmonary toxicity during nitrofurantoin therapy should maintain a high index of suspicion for the drug usage among patients with non-resolving pulmonary symptoms. Alternatively, the use of other antimicrobial agents with a better risk-to-benefit ratio should be considered.
Keywords: Lung, nitrofurantoin, toxicity
Current Drug Safety
Title: Nitrofurantoin Pulmonary Toxicity: Neglected Threat
Volume: 5 Issue: 2
Author(s): Emilia Hardak, Gidon Berger, Norberto Krivoy, Anna Solomonov and Mordechai Yigla
Affiliation:
Keywords: Lung, nitrofurantoin, toxicity
Abstract: Nitrofurantoin lung toxicity was diagnosed among ten patients receiving 50 mg/day to prevent recurrent urinary tract infection. In six patients a symptomatic period of 3-36 months preceded the diagnosis. All but one patient, with irreversible lung injury at presentation recovered completely, five after drug discontinuation and four after steroids therapy. Large amount of data regarding unexpected, sometimes severe pulmonary toxicity during nitrofurantoin therapy should maintain a high index of suspicion for the drug usage among patients with non-resolving pulmonary symptoms. Alternatively, the use of other antimicrobial agents with a better risk-to-benefit ratio should be considered.
Export Options
About this article
Cite this article as:
Hardak Emilia, Berger Gidon, Krivoy Norberto, Solomonov Anna and Yigla Mordechai, Nitrofurantoin Pulmonary Toxicity: Neglected Threat, Current Drug Safety 2010; 5 (2) . https://dx.doi.org/10.2174/157488610790936169
DOI https://dx.doi.org/10.2174/157488610790936169 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Nonstandard Drugs and Feasible New Interventions for Autoimmune Hepatitis: Part I
Inflammation & Allergy - Drug Targets (Discontinued) Neuropsychiatric Systemic Lupus Erythematosus
Current Neuropharmacology The Neutrophil: An Underappreciated But Key Player in SLE Pathogenesis
Current Immunology Reviews (Discontinued) Perivascular Inflammation and Hypertensive Cardiovascular Remodeling
Current Hypertension Reviews Endothelial Expression of MHC Class II Molecules in Autoimmune Disease
Current Pharmaceutical Design Mixed Connective Tissue Disease, a Roundabout to Rheumatic Diseases?
Current Rheumatology Reviews Anti-IgE Therapy with Omalizumab for Severe Asthma: Current Concepts and Potential Developments
Current Drug Targets Neuroprotection by Diazoxide in Animal Models for Cerebrovascular Disorders
Vascular Disease Prevention (Discontinued) ATP-Sensitive Potassium Channel Modulators and Cardiac Arrhythmias: An Update
Current Pharmaceutical Design The Risk of Progressive Multifocal Leukoencephalopathy Under Biological Agents Used in the Treatment of Chronic Inflammatory Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Nimodipine Reappraised: An Old Drug With a Future
Current Neuropharmacology The Rationale for Comparative Studies of Accelerated Atherosclerosis in Rheumatic Diseases
Current Vascular Pharmacology Oxidative-Nitrosative Stress In Hypertension
Current Vascular Pharmacology Prevention of Endothelial Dysfunction and Cardiovascular Disease by n-3 Fatty Acids-Inhibiting Action on Oxidative Stress and Inflammation
Current Pharmaceutical Design Recent Insights into COVID-19 in Children and Clinical Recommendations
Current Pediatric Reviews Novel Approaches to the Therapy of Rheumatoid Arthritis based on an Understanding of Disease Mechanisms
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) The Role of Anti-Inflammatory Drugs in Respiratory Diseases - Pirfenidone, Penicillamine, Chloroquine and Chlorambucil
Current Respiratory Medicine Reviews Current Therapeutic Approaches in Inflammatory Bowel Disease
Current Pharmaceutical Design Mixed Connective Tissue Disease (MCTD) and Undifferentiated Connective Tissue Disease (UCTD)
Current Rheumatology Reviews Substance Abuse and Movement Disorders: Complex Interactions and Comorbidities
Current Drug Abuse Reviews